Literature DB >> 32908254

Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.

Stuart J Schnitt1,2.   

Abstract

Concerns about overdiagnosis and overtreatment have led to interest in de-escalating treatment for ductal carcinoma in situ (DCIS). This article reviews the epidemiology, natural history, and current treatment options for DCIS and discusses ongoing efforts to further de-escalate treatment for these patients.

Entities:  

Year:  2020        PMID： 32908254     DOI： 10.1038/s41379-020-00665-x

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  39 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  Harold J Burstein; Kornelia Polyak; Julia S Wong; Susan C Lester; Carolyn M Kaelin
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 2.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

3.  De-escalating and escalating systemic therapy of early breast cancer.

Authors:  Ian E Smith; Alicia F C Okines
Journal:  Breast       Date:  2017-07-08       Impact factor: 4.380

Review 4.  Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.

Authors:  Wedad M Hanna; Carlos Parra-Herran; Fang-I Lu; Elzbieta Slodkowska; Eileen Rakovitch; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2019-02-13       Impact factor: 7.842

5.  The heterogeneity of cancer.

Authors:  H Gilbert Welch
Journal:  Breast Cancer Res Treat       Date:  2018-02-02       Impact factor: 4.872

Review 6.  De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

Authors:  E Shelley Hwang; Lawrence Solin
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

7.  De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.

Authors:  Matteo Lazzeroni; Andrea DeCensi
Journal:  J Clin Oncol       Date:  2020-03-03       Impact factor: 44.544

8.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors:  G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

Review 9.  The natural history of ductal carcinoma in situ of the breast: a review.

Authors:  Bircan Erbas; Elena Provenzano; Jane Armes; Dorota Gertig
Journal:  Breast Cancer Res Treat       Date:  2005-12-01       Impact factor: 4.872

Review 10.  Ductal carcinoma in situ: to treat or not to treat, that is the question.

Authors:  Maartje van Seijen; Esther H Lips; Alastair M Thompson; Serena Nik-Zainal; Andrew Futreal; E Shelley Hwang; Ellen Verschuur; Joanna Lane; Jos Jonkers; Daniel W Rea; Jelle Wesseling
Journal:  Br J Cancer       Date:  2019-07-09       Impact factor: 7.640
View more
  6 in total

1.  Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.

Authors:  Guannan Wang; Alok Kumar; Wanjun Ding; Preethi Korangath; Tapan Bera; Junxia Wei; Priya Pai; Kathleen Gabrielson; Ira Pastan; Saraswati Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-08       Impact factor: 12.779

2.  Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Authors:  Jean L Wright; Habib Rahbar; Samilia Obeng-Gyasi; Ruth Carlos; Judy Tjoe; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2021-11-23       Impact factor: 50.717

Review 3.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

4.  Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.

Authors:  Linyong Wu; Yujia Zhao; Peng Lin; Hui Qin; Yichen Liu; Da Wan; Xin Li; Yun He; Hong Yang
Journal:  BMC Med Imaging       Date:  2021-05-17       Impact factor: 1.930

Review 5.  Challenging, Accurate and Feasible: CAF-1 as a Tumour Proliferation Marker of Diagnostic and Prognostic Value.

Authors:  Alexandros G Sykaras; Alexandros Pergaris; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

Review 6.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

Authors:  Angela Santoro; Giuseppe Angelico; Antonio Travaglino; Frediano Inzani; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Vincenzo Fiorentino; Antonio Raffone; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.